메뉴 건너뛰기




Volumn 26, Issue 4, 2000, Pages 133-138

Evaluation of the effects of zafirlukast 40 MG B.I.D. in addition to preexisting therapy of high-dose inhaled steroids on symptomatic patients with reversible respiratory obstruction: Preliminary data

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; ZAFIRLUKAST;

EID: 0033710482     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (3)

References (21)
  • 3
    • 0030696614 scopus 로고    scopus 로고
    • Increased urinary excretion of LTE4 after exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist
    • (1997) Thorax , vol.52 , pp. 1030
    • Reiss, T.F.1    Hill, J.B.2    Harman, E.3
  • 11
    • 0007005503 scopus 로고    scopus 로고
    • Global initiative for Asthma Management and Prevention (GINA), NHI publication no. 97- 4051, April
    • (1997)
  • 14
    • 0025802839 scopus 로고
    • Lung function improvement in asthma with cysteinyl-leukotriene receptor antagonist
    • (1991) Lancet , vol.337 , pp. 1062
    • Huik, P.1    Bames, N.C.2
  • 17
    • 0030875339 scopus 로고    scopus 로고
    • Zafirlukast for symptomatic mild to moderate asthma: A 13-week therapy multicenter study. Clin. Ther.
    • (1997) , vol.19 , pp. 675
    • Fish, J.E.1    Kemp, J.P.2    Lockey, R.F.3
  • 21
    • 6844250776 scopus 로고    scopus 로고
    • Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast
    • (1998) JAMA , vol.279 , pp. 455
    • Wechsler, M.E.1    Garpestad, E.2    Flier, S.R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.